These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27604766)

  • 1. The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease.
    Luo Y; Friese OV; Runnels HA; Khandke L; Zlotnick G; Aulabaugh A; Gore T; Vidunas E; Raso SW; Novikova E; Byrne E; Schlittler M; Stano D; Dufield RL; Kumar S; Anderson AS; Jansen KU; Rouse JC
    AAPS J; 2016 Nov; 18(6):1562-1575. PubMed ID: 27604766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
    McNeil LK; Donald RGK; Gribenko A; French R; Lambert N; Harris SL; Jones TR; Li S; Zlotnick G; Vogel U; Claus H; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Wang X; Vuong J; Mayer LW; Pride MW; Jansen KU; Anderson AS
    mBio; 2018 Mar; 9(2):. PubMed ID: 29535195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years.
    Shirley M; Dhillon S
    BioDrugs; 2015 Oct; 29(5):353-61. PubMed ID: 26394633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
    Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
    Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neisseria meningitidis Serogroup B Vaccine, Bivalent rLP2086, Induces Broad Serum Bactericidal Activity Against Diverse Invasive Disease Strains Including Outbreak Strains.
    Harris SL; Donald RG; Hawkins JC; Tan C; O'Neill R; McNeil LK; Perez JL; Anderson AS; Jansen KU; Jones TR
    Pediatr Infect Dis J; 2017 Feb; 36(2):216-223. PubMed ID: 27846061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.
    Marshall HS; Richmond PC; Nissen MD; Wouters A; Baber J; Jiang Q; Anderson AS; Jones TR; Harris SL; Jansen KU; Perez JL
    Vaccine; 2013 Mar; 31(12):1569-75. PubMed ID: 23352429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
    Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
    Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
    Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
    Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine.
    Senders S; Bhuyan P; Jiang Q; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Ginis J; Perez JL
    Pediatr Infect Dis J; 2016 May; 35(5):548-54. PubMed ID: 26835974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.
    Ostergaard L; Lucksinger GH; Absalon J; Beeslaar J; Eiden J; Jansen KU; York LJ; Quinn A; Graversen ME; Perez JL
    Vaccine; 2016 Mar; 34(12):1465-71. PubMed ID: 26845739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
    Vesikari T; Østergaard L; Diez-Domingo J; Wysocki J; Flodmark CE; Beeslaar J; Eiden J; Jiang Q; Jansen KU; Jones TR; Harris SL; O'Neill RE; York LJ; Crowther G; Perez JL
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):152-60. PubMed ID: 26407272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
    Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
    Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MenB-FHbp Meningococcal Group B Vaccine (Trumenba
    Shirley M; Taha MK
    Drugs; 2018 Feb; 78(2):257-268. PubMed ID: 29380290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
    Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
    Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
    Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
    Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.
    Marshall HS; Richmond PC; Nissen MD; Jiang Q; Anderson AS; Jansen KU; Reynolds G; Ziegler JB; Harris SL; Jones TR; Perez JL
    Pediatr Infect Dis J; 2012 Oct; 31(10):1061-8. PubMed ID: 22718089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neisseria meningitidis serogroup B bivalent factor H binding protein vaccine.
    Brendish NJ; Read RC
    Expert Rev Vaccines; 2015 Apr; 14(4):493-503. PubMed ID: 25703792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups.
    Hoiseth SK; Murphy E; Andrew L; Vogel U; Frosch M; Hellenbrand W; Abad R; Vazquez JA; Borrow R; Findlow J; Taha MK; Deghmane AE; Caugant DA; Kriz P; Musilek M; Mayer LW; Wang X; Macneil JR; York L; Tan CY; Jansen KU; Anderson AS
    Pediatr Infect Dis J; 2013 Oct; 32(10):1096-101. PubMed ID: 23694830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on generalized modules for membrane antigens (GMMA).
    Koeberling O; Ispasanie E; Hauser J; Rossi O; Pluschke G; Caugant DA; Saul A; MacLennan CA
    Vaccine; 2014 May; 32(23):2688-95. PubMed ID: 24704334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.